Business context and reporting period
This Form 10-Q is for GlycoMimetics, Inc., a clinical-stage biotechnology company, for the quarter ended June 30, 2017; it does not appear to be a filing by Crescent BioPharma, Inc., as indicated in the request metadata. The company develops glycomimetic drug candidates and has no approved products or product-sales revenue.
Key programs included rivipansel, licensed to Pfizer; GMI-1271 for acute myeloid leukemia (AML) and multiple myeloma (MM); and GMI-1359, which was in early clinical development.
Financial results and position
| Metric | Q2 2017 / June 30, 2017 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q2 2016 |
| Research and development expense | $5.72 million for Q2; $11.60 million for first half | $5.78 million and $11.30 million, respectively, in 2016 |
| General and administrative expense | $2.52 million for Q2; $4.61 million for first half | $2.31 million and $4.37 million, respectively, in 2016 |
| Net loss | $8.14 million for Q2; $16.07 million for first half | $8.07 million and $15.63 million, respectively, in 2016 |
| Basic and diluted loss per share | $0.30 for Q2; $0.63 for first half | $0.41 and $0.80, respectively, in 2016 |
| Cash and cash equivalents | $119.15 million | $40.04 million at December 31, 2016 |
| Total assets / total liabilities | $121.62 million / $6.19 million | $42.39 million / $7.09 million at December 31, 2016 |
| Operating cash flow | $(15.17) million for first half | $(16.30) million for first half 2016 |
| Financing cash flow | $94.50 million for first half | $22.63 million for first half 2016 |
No debt balance is reported in the presented balance sheet. Profit margins are not meaningful given zero revenue and operating losses.
Material changes versus the prior comparable period
- First-half net loss increased by $0.45 million, while Q2 net loss increased by $0.07 million year over year. First-half operating expenses rose by $0.55 million; higher GMI-1271 clinical costs and personnel and stock compensation were partly offset by lower manufacturing and development costs, including for GMI-1359.
- Cash increased by $79.11 million during the first half, primarily from financing: a May public offering generated $86.8 million net proceeds, and at-the-market sales generated $7.4 million net proceeds. The offerings increased common shares outstanding.
- First-half operating cash use declined by $1.14 million year over year. Cash and cash equivalents were $119.1 million at June 30, 2017.
Outlook, commentary, risks and unusual items
- Management expected existing cash and cash equivalents to fund operating and capital expenditure needs at least through the second half of 2019. This estimate depends on assumptions that could prove incorrect; the company expects continued losses and negative operating cash flows and may need additional financing.
- Management planned to provide further GMI-1271 trial updates in the second half of 2017 and in 2018, and to discuss potential Phase 3 trial design with the FDA. The Phase 1/2 AML trial had completed enrollment at 91 patients. Reported interim results included a 41% CR/CRi rate among 54 evaluable relapsed/refractory patients, 7% 60-day mortality in that group, and a 68% CR/CRi rate among 25 newly diagnosed elderly patients. These are clinical observations, not confirmed evidence of approval or commercial success.
- The company was expanding GMI-1359 healthy-volunteer enrollment and anticipated selecting a cancer indication and dose for further evaluation in 2018. It was enrolling patients in its GMI-1271 MM trial and planning additional European sites.
- Pfizer’s rivipansel collaboration offers potential future development, regulatory and sales milestones and royalties, but timing and achievement are uncertain. No Pfizer revenue or milestone payments were recorded in the periods presented.
- Principal risks include clinical-trial outcomes and enrollment, regulatory approval, manufacturing, commercialization, reimbursement, competition and access to additional capital. The filing states risk factors had not materially changed from the 2016 Form 10-K. No material legal proceedings or off-balance-sheet arrangements were reported. Management assessed disclosure controls as effective.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is GlycoMimetics, Inc.’s 2017 second-quarter Form 10-Q, not a Crescent BioPharma filing.
- Verify clinical-trial updates, data maturity and any subsequent FDA discussions or trial plans; interim response results do not establish efficacy or approval.
- Assess the assumptions behind the cash runway through the second half of 2019, expected development spending and potential need for further financing and dilution.
- Review the status and terms of Pfizer milestones and royalties, which are contingent and produced no revenue in the quarter or first half.